Enterprise Innovation

Translating Research into Next Generation Care Through Collaboration

Based in New York City, Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

Read More About Us

Enterprise Innovation Metrics from FY18 to FY23

520
New Tech Disclosures
183
Issued US Patents
152
Licenses and Options
29
NewCo Launches
Two researchers in PPE doing experiment
For Inventors and Innovators
Learn about how to collaborate with our team of top-tier business development professionals to bring your innovations to life.
Two men in dark blue suits shaking hands and two women at the table smiling
For Industry, Investors and Partners
Learn about groundbreaking innovations you can partner to fuel a pipeline or launch a new venture.

  

A Caucasian and an Indian woman holding some booklets and talking
Innovation Ecosystem
Learn more about the infrastructure and different components of Enterprise Innovation.
Four medical students in white coats sitting at a table and listening to a lecture
Programs, Offerings and Support
Explore entrepreneurial programming and education offered by Enterprise Innovation and our ecosystem partners.

  

Technology Portfolio

Enterprise Innovation brings together the power of industry-leading translational research and clinical care combined with top-tier business development expertise to accelerate innovation to market. Our leading technology portfolio encompasses major pillars of biomedical innovation.

  

Two doctors and two business reps talking
Collaboration Opportunities
Check out our available research opportunities for potential collaborations.

  

Events

Bayer logo and the title
May 13,2024
11:00am to 12:00pm
Bayer's Expert Mondays Webinar: Cell & Gene Regulatory Jungle in
An African-American female scientist wearing goggles and a white coat holding a test tube inside a lab.
May 14,2024
12:00pm to 12:45pm
NSF I-Corps Virtual Information Session
A Caucasian woman wearing a white shirt and dark blue pants working on a small robot next to a computer screen
May 15,2024
9:00am to 5:00pm
I-Corps Regional Course hosted by University at Buffalo
Caucasian man with dark hair and a mustache
May 16,2024
2:00pm to 4:00pm
CTL at Weill Cornell Office Hours with James Bellush

Testimonials

Dr. John Leonard
John P. Leonard, M.D., Senior Associate Dean of Innovation and Initiatives
Getting new innovations across the finish line requires collaboration, often with industry partners, to scale up findings for application in healthcare. Ultimately, we want the work we do here to have a real impact on patients. By fostering an entrepreneurial environment, we can do that.
Lisa Placanica, Ph.D.
Lisa Placanica, Ph.D., Senior Managing Director of the Center for Technology Licensing
There’s obviously fantastic research being done at Weill Cornell Medicine. So we want to work with faculty to identify aspects of their research that could be shaped into a product or a service, work with them to develop it and then to forge the partnership with a commercial entity. We also have to have a finger on the pulse of what industry is looking for: what venture firms are investing in, what pharma is trying to fill their pipeline with. And then we make connections between the two. We have to speak the language between the commercial enterprise and the academic researcher.
Neel Madhukar, Ph.D.
Neel Madhukar, Ph.D., Former Postdoc of the Elemento Lab and current CEO of OneThree Biotech
Taking a new technology from an idea to a company is a daunting process for first-time entrepreneurs – and especially in areas like commercialization which isn't a focus of most doctoral work. One thing that helps this is a community of scientists and entrepreneurs who have been through this before and help guide the way. In this way, resources such as the eLab’s Entrepreneurs-in-Residence are invaluable assets.
Francis Barany, Ph.D.
Francis Barany, Ph.D., Professor of Microbiology and Immunology and National Academy of Inventors Fellow
The professionals at Enterprise Innovation possess strong first-hand knowledge of what it takes to start a company. Their expertise is vital to aspiring faculty scientist/entrepreneurs to launch new companies. Their guidance and feedback has been invaluable throughout the process – they are now helping me with my third company launch.

News

illustration of chromatin in the nucleus

GoT-ChA: A New Tool for Detailing How Gene Mutations Affect Cells

May 8, 2024

A team co-led by researchers at Weill Cornell Medicine and the New York Genome Center has developed an advanced method for revealing how gene mutations disrupt the normal packaging of DNA. These structural changes, which alter patterns of gene activity in a cell, are known as epigenetic changes and can lead to malignancy.

Daedalus Fund Aims to Advance Translational Studies to Next Stages

April 30, 2024

The Daedalus Fund for Innovation, a unique de-risking program of Weill Cornell Medicine Enterprise Innovation, announced its recipients for funding this year.